These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28639285)

  • 1. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.
    Korsak B; Almeida GM; Rocha S; Pereira C; Mendes N; Osório H; Pereira PMR; Rodrigues JMM; Schneider RJ; Sarmento B; Tomé JPC; Oliveira C
    Int J Cancer; 2017 Oct; 141(7):1478-1489. PubMed ID: 28639285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
    Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
    Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
    Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
    Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
    Ito K; Mitsunaga M; Arihiro S; Saruta M; Matsuoka M; Kobayashi H; Tajiri H
    BMC Cancer; 2016 Jan; 16():37. PubMed ID: 26810644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
    Cui Y; Li SB; Peng XC; Wu J; Fu GH
    Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
    An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
    Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
    Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
    Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional trastuzumab-chlorin e6 conjugate for the treatment of HER2-positive human breast cancer.
    Kim KS; Kim J; Kim DH; Hwang HS; Na K
    Biomater Sci; 2018 May; 6(5):1217-1226. PubMed ID: 29578555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2.
    Wu J; Zhao Q; Zhao Y; Zhang X; Tian Y; Guo Z
    Sci Rep; 2021 Mar; 11(1):6993. PubMed ID: 33772068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
    Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
    Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
    Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
    Qiao J; Feng M; Zhou W; Tan Y; Yang S; Liu Q; Wang Q; Feng W; Pan Y; Cui L
    Gastric Cancer; 2024 Jul; 27(4):785-801. PubMed ID: 38782859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
    Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
    Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.